GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Eli Lilly and Company
Eli Lilly shares reflect breakthroughs in modern pharmaceuticals. The company's success and rapid growth are driven by strong demand for innovative diabetes and obesity treatments, such as Mounjaro and Zepbound. The chart is a testament to the success of its R&D division.
Share prices of companies in the market segment - Pharma holding
Eli Lilly is a pharmaceutical giant with key segments in diabetes/obesity treatment, oncology, and immunology. We classify the company in the Pharma holdings sector, and the chart below shows the overall dynamics of the entire large drug manufacturing industry, reflecting investor sentiment.
Broad Market Index - GURU.Markets
Eli Lilly is a global pharmaceutical leader, having made breakthroughs in the treatment of diabetes and obesity. Its rapid market capitalization growth has made it a key driver of the GURU.Markets index. The chart below represents the entire market. Find out how the company is outperforming the overall trend.
Change in the price of a company, segment, and market as a whole per day
LLY - Daily change in the company's share price Eli Lilly and Company
The daily price change for Eli Lilly, a leading pharmaceutical company, is a measure of its reaction to clinical trial results and regulatory announcements. While the graph of these fluctuations may be unspectacular, it is important for the formula system on System.GURU.Markets, where it is used to assess risk.
Daily change in the price of a set of shares in a market segment - Pharma holding
The pharmaceutical industry is one of the most dynamic sectors. This chart reflects its average daily volatility, influenced by news about clinical trials and patents. For the giant Eli Lilly and Company, it serves as a benchmark, allowing them to compare their own stability with the overall industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Eli Lilly is one of the world's largest pharmaceutical companies, having become a leader thanks to breakthrough drugs. Its success has made it a market heavyweight, capable of influencing indices. The chart below shows overall market fluctuations, to which biotech giants like Lilly are increasingly contributing.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Eli Lilly and Company
Eli Lilly has become a pharmaceutical star over the past year thanks to the colossal success of its diabetes and obesity drugs. Its stock price performance, shown in the chart, is a direct reflection of this blockbuster. Investors were assessing the company's ability to meet overwhelming demand and develop its future drug pipeline.
Annual dynamics of market capitalization of the market segment - Pharma holding
Eli Lilly achieved breakthroughs with its blockbuster diabetes and obesity drugs. This success fueled explosive share price growth, which stands out against the more subdued performance of the overall pharmaceutical sector. The chart below clearly illustrates how a single innovative product can reposition an entire company.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Eli Lilly is an example of how a pharmaceutical company can become a key driver of market growth. Although the healthcare sector is considered defensive, the success of blockbusters in diabetes and weight loss has given Lilly shares a trajectory comparable to tech giants. Its performance demonstrates how a single breakthrough product can eclipse any economic cycle.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Eli Lilly and Company
For Eli Lilly, monthly price fluctuations are a chronicle of its pharmaceutical breakthroughs. The chart reflects investor reactions to clinical trial results, particularly for blockbuster drugs in diabetes and weight loss, regulatory decisions (FDA), and patent protection news, which determine future cash flows.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart reflects the pulse of the entire pharmaceutical sector, where Eli Lilly has recently emerged as a leading innovator. Industry momentum has been driven by breakthroughs in diabetes and obesity treatments, as well as overall investments in biotechnology. This is the backdrop against which Eli Lilly has made its impressive leap.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects the overall market sentiment. For Eli Lilly, which has become one of the world's largest pharmaceutical companies, it's merely the backdrop. Its own growth story, fueled by revolutionary drugs, was so powerful that the company lived by its own rules, virtually ignoring market fluctuations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Eli Lilly and Company
Eli Lilly is a biopharmaceutical company whose stock follows the rhythm of research and development news. Weekly price fluctuations are often driven by the publication of clinical trial results, regulatory approvals of new drugs, or patent news. The chart shows investor reactions to scientific breakthroughs and commercial potential.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Eli Lilly, thanks to its breakthrough drugs, has recently often acted as a driving force for the entire pharmaceutical sector. News of clinical trials or sales of its blockbusters can boost not only its shares but also the entire biotech sector. The chart shows how far this innovative company's performance outpaces the industry average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Eli Lilly, thanks to breakthrough drugs for diabetes and obesity, has become one of the world's largest pharmaceutical companies. Its shares are currently living in the rhythm of news about the success of these blockbusters. The chart will show how well its unique growth story allows it to defy general market fluctuations.
Market capitalization of the company, segment and market as a whole
LLY - Market capitalization of the company Eli Lilly and Company
Eli Lilly's explosive growth in market capitalization, visible on the chart, is a clear example of how the market values pharmaceutical breakthroughs. The company's valuation soared thanks to the blockbuster success of its diabetes and obesity drugs. The stock price dynamics reflect investor expectations that these drugs will transform the industry and generate billions in revenue for the company.
LLY - Share of the company's market capitalization Eli Lilly and Company within the market segment - Pharma holding
Eli Lilly, thanks to breakthrough drugs, has captured a huge share of the pharmaceutical sector. Its rapidly growing market capitalization reflects its leadership in developing blockbuster diabetes and obesity drugs. The chart shows how innovation can transform a company into a dominant player.
Market capitalization of the market segment - Pharma holding
The chart below shows the combined value of pharmaceutical giants, and Eli Lilly stands out as one of the main growth drivers. Thanks to breakthrough drugs in diabetes and obesity, the company isn't just competing, it's setting the pace for the entire industry. The growth in the entire sector's market capitalization is largely due to the success of its innovative developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Eli Lilly demonstrates how a single scientific breakthrough in pharmaceuticals can change everything. The success of its new drugs has created value comparable to entire industries. The chart below vividly illustrates how intellectual property can account for a huge share of the global economy.
Book value capitalization of the company, segment and market as a whole
LLY - Book value capitalization of the company Eli Lilly and Company
Eli Lilly's foundation isn't factories in the classic sense, but cutting-edge research laboratories, production facilities for complex biologics, and a patent portfolio worth billions of dollars. Its book value reflects the company's science-intensive base. The graph is a financial reflection of multi-year R&D cycles, where each breakthrough is reflected in asset growth.
LLY - Share of the company's book capitalization Eli Lilly and Company within the market segment - Pharma holding
Every Eli Lilly drug is backed by years of research in state-of-the-art laboratories and production at massive pharmaceutical plants. The chart shows the company's share of the industry's tangible assets. This represents its scientific and manufacturing potential, translated into tangible infrastructure that saves lives.
Market segment balance sheet capitalization - Pharma holding
Pharmaceuticals are a capital-intensive business, but the sources of value are varied. The sector's asset portfolio is enormous, but for Eli Lilly, its most important capital is intellectual capital invested in R&D. While its manufacturing facilities are important, it's its ability to create breakthrough drugs that sets it apart from its competitors, making it "capital-intensive" in the scientific sense.
Book value of all companies included in the broad market index - GURU.Markets
Eli Lilly is one of the driving forces of modern pharmaceuticals. Its book value reflects not only its production capacity but also its colossal investments in research and patents for life-saving drugs. This is real capital, dedicated to fighting the most complex diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Eli Lilly and Company
Eli Lilly's book value comes from its labs and factories. But its market capitalization is a bet on the future of medicine. The chart shows the astronomical premium investors are paying for its portfolio of blockbuster diabetes and obesity treatments, as well as its hopes for a cure for Alzheimer's.
Market to book capitalization ratio in a market segment - Pharma holding
Eli Lilly is a pharmaceutical company whose value is determined not by its pill factories, but by its portfolio of patents for breakthrough drugs, such as those for diabetes and obesity. The market prices these blockbusters based on future revenues. This chart shows how much expectations for its R&D and future sales exceed the value of its current tangible assets.
Market to book capitalization ratio for the market as a whole
Eli Lilly is a leading pharmaceutical company, valued by its portfolio of patented drugs and future developments. This chart reflects average market valuations. The premium investors place on Lilly is driven by its innovation and potential for blockbusters, which are valued significantly higher than the value of its laboratories and factories.
Debts of the company, segment and market as a whole
LLY - Company debts Eli Lilly and Company
For Eli Lilly, a leading pharmaceutical company, debt is a key source of funding innovation. Developing new drugs requires billions of dollars in investments in years of research and clinical trials. This chart shows how the company uses debt to fund its future product portfolio and organic growth.
Market segment debts - Pharma holding
Eli Lilly is a pharmaceutical company whose success depends on multibillion-dollar investments in research and development of new drugs. Debt is often used to finance R&D and, more importantly, to acquire biotech startups with promising developments. This chart shows how aggressively the company uses leverage to fuel growth.
Market debt in general
Eli Lilly is a pharmaceutical giant whose revenue depends on the success of years of expensive research into new drugs. Developing blockbuster drugs requires not only scientific genius but also a well-thought-out financial strategy. The chart shows the overall picture of its debt obligations, allowing us to assess how Eli Lilly finances its growth and manages risk.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Eli Lilly and Company
Eli Lilly's success depends on years of expensive research into new drugs, such as those for diabetes and obesity. This chart illustrates the company's financial strategy for raising funds for R&D and acquiring promising biotech companies. Debt allows the company to bet heavily on future blockbusters, but trial failures could increase the risks.
Market segment debt to market segment book capitalization - Pharma holding
Eli Lilly is one of the world's leading pharmaceutical companies, whose research and development of new drugs requires billions of dollars in investments. This chart allows you to assess how conservatively or aggressively the company uses debt to finance R&D compared to the financial health of the pharmaceutical industry as a whole.
Debt to book value of all companies in the market
Eli Lilly is a leading pharmaceutical company, investing billions in drug development. This chart allows us to assess its financial strategy against the backdrop of the overall economy. It shows how its debt policy, aimed at funding expensive R&D, differs from the average debt burden across the market.
P/E of the company, segment and market as a whole
P/E - Eli Lilly and Company
This metric for Eli Lilly reflects tremendous investor optimism. Thanks to breakthrough drugs in diabetes and obesity treatments, the company has become a star in the pharmaceutical industry. The very high P/E suggests that the market is pricing in future multibillion-dollar revenues from these blockbusters, expecting continued phenomenal growth.
P/E of the market segment - Pharma holding
Eli Lilly is a pharmaceutical giant developing breakthrough drugs in diabetes, oncology, and immunology. The valuation of such companies is heavily dependent on their patent portfolio and future developments. This chart shows the average valuation for the entire pharmaceutical industry, serving as a benchmark for understanding whether expectations for Eli Lilly are above or below the market average.
P/E of the market as a whole
Eli Lilly and Company is a pharmaceutical giant whose valuation depends on success in developing new drugs, particularly in areas such as diabetes and obesity. Unlike cyclical companies, its business is less susceptible to overall market sentiment, as illustrated by this chart. For Eli Lilly, lab news is more important than the overall economic climate.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Eli Lilly and Company
Eli Lilly's valuation is closely tied to its pharmaceutical portfolio and future blockbusters. This chart reflects investor confidence in the commercial potential of the company's breakthrough drugs, particularly in diabetes and obesity treatments. The trend shows how much of the future excess profits from these drugs are already priced into the current share price.
%20P%2FE%20Eli%20Lilly%20and%20Company&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Eli-Lilly-and-Company&v=1772513841050 "Chart of the company's future (projected) P/E Eli Lilly and Company")
Future (projected) P/E of the market segment - Pharma holding
Eli Lilly achieved breakthroughs thanks to its blockbuster diabetes and obesity drugs. This chart reflects the market's high expectations for the company's future growth. By comparing its projected earnings with those of the pharmaceutical sector, one can estimate the premium investors are pricing into its stock in anticipation of outperformance.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772513841051 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Eli Lilly has become a leader in the pharmaceutical industry thanks to its breakthrough drugs. This chart of overall market valuations is important, but the pharmaceutical sector often operates by its own rules, depending on the success of clinical trials. Nevertheless, overall risk appetite influences biotech company valuations, making Eli Lilly more or less attractive to investors.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513841054 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company whose revenue is generated by developing and selling innovative drugs, particularly in diabetes and oncology. This chart reflects the life cycle of its blockbuster drugs: from successful clinical trials and launch to patent expiration.
Profit of companies in the market segment - Pharma holding
Eli Lilly and Company is a pharmaceutical giant whose innovations in diabetes and obesity treatments have created blockbuster drugs. The success of such breakthrough drugs can single-handedly raise the profitability bar for the entire pharmaceutical industry. This chart illustrates how scientific advances and successful launches of new products fundamentally change the financial landscape of the sector.
Overall market profit
Eli Lilly and Company is a global pharmaceutical leader, developing treatments for diabetes, cancer, and autoimmune diseases. The company's success in bringing new drugs to market not only saves lives but also generates enormous revenues. This reflects both the needs of an aging population and the ability of an innovative economy to create high-margin products.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Eli Lilly and Company
Eli Lilly achieved breakthroughs with blockbuster diabetes and obesity drugs. This chart demonstrates the market's enormous sales expectations for these drugs. The company's future profits depend almost entirely on successfully scaling up production and further penetration into global markets.
%20profit%20of%20the%20company%20Eli%20Lilly%20and%20Company&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Eli-Lilly-and-Company&v=1772513841091 "Graph of future (projected) profit of the company Eli Lilly and Company")
Future (predicted) profit of companies in the market segment - Pharma holding
Eli Lilly is a pharmaceutical giant that has made breakthroughs in diabetes and obesity treatment with drugs like Mounjaro and Zepbound. The data in the chart shows revenue forecasts for the entire pharmaceutical industry. This allows us to assess the potential of Lilly's unique product portfolio to drive growth that outpaces overall healthcare trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772513841097 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Eli Lilly's profit trajectory is largely determined by the success of its blockbuster drugs in diabetes and obesity. This chart reflects the enormous sales expectations for these drugs and the state of the company's product portfolio in other therapeutic areas. The trend is sensitive to news about clinical trials, patents, and the competitive environment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513841110 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Eli Lilly and Company
Eli Lilly is a pharmaceutical company whose revenue is directly dependent on the success of its drugs. This chart shows investor expectations for the future of its drug portfolio. A high multiple often indicates market confidence in potential blockbusters and future sales growth, which is priced into the current price.
P/S market segment - Pharma holding
Eli Lilly is a leading global pharmaceutical company focused on developing breakthrough drugs in diabetes, oncology, and immunology. This chart shows how the market averages value pharmaceutical industry revenue. It helps understand whether Eli Lilly's valuation reflects a premium for its pipeline of promising drugs.
P/S of the market as a whole
Eli Lilly is a pharmaceutical company whose revenue is directly dependent on the success of its patented drugs and new developments. The drug life cycle makes its revenue cyclical. The chart presented here serves as a market benchmark for revenue valuation. For Eli Lilly, it helps understand how highly the market values its drug portfolio and its belief in future blockbusters.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Eli Lilly and Company
Eli Lilly achieved breakthroughs in diabetes and obesity treatment with its blockbuster drugs Mounjaro and Zepbound. This chart shows how investors estimate the company's future revenue based on sales projections for these drugs. This level reflects the market's enormous expectations for Eli Lilly's ability to dominate the multibillion-dollar weight loss market.
%20P%2FS%20Eli%20Lilly%20and%20Company&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Eli-Lilly-and-Company&v=1772513841140 "The graph of the company's future (projected) P/S Eli Lilly and Company")
Future (projected) P/S of the market segment - Pharma holding
Eli Lilly is a pharmaceutical company that has made breakthroughs in diabetes and obesity treatments, fueling a meteoric rise in its stock price. This metric reflects how much its future sales expectations outpace those of other pharma giants. Does the current valuation reflect a belief in the long-term dominance of its blockbusters, or does the market already consider it overheated?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772513841170 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Eli Lilly is a pharmaceutical giant whose revenue depends on the success of new drugs, particularly in areas such as diabetes and obesity. The company's growth forecasts can have a significant impact on overall market expectations, as represented by this chart. The commercial success of its blockbusters is a growth driver for the entire healthcare sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513841171 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company focused on developing breakthrough medicines in areas such as diabetes, oncology, and immunology. This chart shows the commercial success of its drugs, reflecting the demand from healthcare systems and patients for innovative treatments worldwide.
Sales of companies in the market segment - Pharma holding
Eli Lilly is one of the world's leading pharmaceutical companies, focused on developing breakthrough drugs in areas such as diabetes and oncology. Its success depends on innovation and patents. The graph below shows the total revenue of the pharmaceutical sector, demonstrating the overall market size and growth rate, where Eli Lilly is vying for its share.
Overall market sales
Eli Lilly and Company is a global pharmaceutical company developing drugs in key areas such as diabetes and oncology. Its success depends on innovation and demographic trends. While this total revenue chart isn't directly related, it reflects the ability of the healthcare system and consumers to pay, which indirectly impacts the availability of its drugs on the market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Eli Lilly and Company
Eli Lilly achieved breakthroughs with its blockbuster diabetes and obesity drugs. The company's future revenue is directly dependent on the growth rate of these drugs and the success of its research and development. This chart represents Wall Street's bet on how long the company can sustain phenomenal demand for its key products.
%20sales%20of%20the%20company%20Eli%20Lilly%20and%20Company&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Eli-Lilly-and-Company&v=1772513841207 "Schedule of future (projected) sales of the company Eli Lilly and Company")
Future (projected) sales of companies in the market segment - Pharma holding
Eli Lilly and Company is a global pharmaceutical company focused on developing breakthrough medicines in diabetes, oncology, and immunology. This chart displays projected revenues for the entire pharmaceutical sector. It allows for an assessment of overall industry trends, such as rising healthcare costs and demand for innovative drugs, which are important to Lilly.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772513841210 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Pharmaceutical giant Eli Lilly might seem less dependent on economic cycles. However, this chart is important for understanding the overall ability of the healthcare system and consumers to afford innovative drugs. The success of the company's new blockbusters depends not only on their effectiveness but also on the overall economic climate, which determines healthcare budgets and the population's ability to pay.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513841215 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Eli Lilly and Company
Eli Lilly is a pharmaceutical company focused on developing breakthrough drugs in areas such as diabetes and oncology. This chart shows the high return on investment (ROI) for successful, patent-protected blockbuster drugs. A sharp increase in this indicator often coincides with the launch of a new, game-changing drug.
Market segment marginality - Pharma holding
Eli Lilly is a pharmaceutical company focused on developing innovative, patent-protected drugs. Successful launches of blockbusters in areas such as diabetes and oncology provide the company with exclusivity and significant pricing power. This metric demonstrates how its portfolio of in-demand drugs generates significantly above-average profit margins.
Market marginality as a whole
Eli Lilly is a pharmaceutical giant whose profitability depends on the success of scientific research and patent protection for blockbuster drugs. This chart reflects average profitability in an economy where price pressure is the norm. Eli Lilly, however, demonstrates a business model with potentially enormous profitability, protected from competition for years to come thanks to exclusive rights to its drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Eli Lilly and Company
Eli Lilly is a pharmaceutical company behind breakthrough drugs in diabetes and oncology. This chart shows its intellectual capital—the scientists, researchers, and specialists who lead the development of new drugs. The team's growth is directly related to investments in R&D, clinical trials, and expanding its commercial presence in global markets.
Share of the company's employees Eli Lilly and Company within the market segment - Pharma holding
This chart shows Eli Lilly's weight in the pharmaceutical industry, measured by human capital. The significant share of employees in the sector underscores the scale of its research and development and commercial operations. It illustrates the company's massive investment in scientists, physicians, and specialists working to develop and advance new breakthrough drugs.
Number of employees in the market segment - Pharma holding
Eli Lilly is one of the world's leading pharmaceutical companies, whose success depends on the highly skilled scientists, researchers, and chemists. Developing new drugs is a marathon, requiring decades and thousands of specialists. This graph illustrates the research-intensive nature of the pharmaceutical industry, where companies like Eli Lilly are magnets for the best scientific talent.
Number of employees in the market as a whole
Eli Lilly is one of the world's leading pharmaceutical companies, experiencing a boom thanks to breakthrough drugs for diabetes and obesity (Mounjaro/Zepbound). This chart reflects the economic base that funds healthcare. Stable employment means more people have private insurance that covers these innovative (and expensive) drugs, providing Lilly with a huge cash flow.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Eli Lilly and Company (LLY)
Eli Lilly is a company where value is created in laboratories. A small group of scientists can discover a blockbuster drug worth tens of billions of dollars. This exceptional value reflects not current productivity, but the colossal market valuation of its intellectual property—the patents on future drugs.
%20of%20the%20company%20Eli%20Lilly%20and%20Company%20(LLY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Eli-Lilly-and-Company-LLY&v=1772513841273 "Chart of market capitalization per employee (in thousands of dollars) of the company Eli Lilly and Company (LLY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Eli Lilly is pure science and intellectual property. The company's value lies not in its machines, but in its patents for blockbusters like Mounjaro. In pharma, a small R&D team can create billions in value. This chart reflects this reality, showing the enormous market value generated by each employee in this R&D race.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772513841287 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Eli Lilly is a pharmaceutical company focused on developing innovative drugs. The high market valuation per employee, reflected in this chart, is the result of years of investment in R&D. The company's value is embedded in the patents and intellectual property created by a relatively small team of highly skilled scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513841302 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Eli Lilly and Company (LLY)
Eli Lilly is a pharmaceutical giant behind breakthrough drugs (for example, in diabetes and weight loss). Pharma is a high-stakes business: years of R&D and billions in investments. This chart shows how successful patents (blockbusters) recoup all costs. A high figure here means that every employee reaps the rewards of successful developments.
%20Chart%20Eli%20Lilly%20and%20Company%20(LLY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Eli-Lilly-and-Company-LLY&v=1772513841322 "Company Profit Per Employee (in thousands of dollars) Chart Eli Lilly and Company (LLY)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Eli Lilly is an innovative pharmaceutical company. This chart shows the industry average. In this sector, labor profitability is high. It's a "blockbuster business": a single successful drug patent can generate billions, more than recouping R&D costs and ensuring high profits per scientist and marketer.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772513841349 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Eli Lilly is a pharmaceutical company whose profits depend on successful scientific developments and drug patents. A team of scientists can create a drug that generates billions of dollars in revenue. This metric illustrates the economics of intellectual property: enormous profitability is achieved through breakthrough ideas, not the size of the workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513841362 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Eli Lilly and Company (LLY)
Eli Lilly is a global pharmaceutical company that creates innovative drugs. This metric reflects the essence of its business: years of research and billions of investments by a small group of scientists lead to the creation of a blockbuster drug that generates massive revenue. This is productivity driven by intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Eli-Lilly-and-Company-LLY&v=1772513841376 "Sales chart per company employee Eli Lilly and Company (LLY)")
Sales per employee in the market segment - Pharma holding
Eli Lilly is a pharmaceutical giant known for developing breakthrough drugs, such as those for diabetes and obesity. This chart shows the average revenue per employee in the segment. It helps assess how effectively the company's investments in R&D and marketing translate into revenue per employee compared to other major pharmaceutical players.
Sales per employee for the market as a whole
Eli Lilly achieved breakthroughs thanks to its blockbuster treatments for diabetes and obesity. Pharmaceuticals is a business where a single successful patent can generate billions. This chart shows how investments in R&D, translated into successful drugs, enable the company to generate enormous revenues that aren't directly dependent on headcount, as in retail or manufacturing.
Short shares by company, segment and market as a whole
Shares shorted by company Eli Lilly and Company (LLY)
Eli Lilly is renowned for its breakthrough drugs, particularly in diabetes and obesity treatments (Mounjaro, Zepbound). This chart shows the bets of those who believe the stock is overheated. Bears point to an extremely high valuation, dependence on the success of several blockbusters, and the risk of increased competition or regulatory pressure on drug prices.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Eli-Lilly-and-Company-LLY&v=1772513841485 "Short Shares Chart for the Company Eli Lilly and Company (LLY)")
Shares shorted by market segment - Pharma holding
Eli Lilly is booming thanks to breakthrough diabetes and obesity drugs that have become blockbusters. But what do investors think about the pharmaceutical industry as a whole? This chart shows the total volume of bets against the entire segment. It helps understand whether the market is anticipating, for example, regulatory pressure or problems for Big Pharma as a whole.
Shares shorted by the overall market
Eli Lilly is a pharmaceutical giant experiencing a boom thanks to its diabetes and obesity treatments (Mounjaro, Zepbound). Although the healthcare sector is considered defensive, Lilly shares trade at a premium valuation based on future growth. When this chart shows rising market fears, investors may take profits even in strong companies to mitigate risk.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Eli Lilly and Company (LLY)
Eli Lilly, a pharmaceutical giant whose valuation depends heavily on the success of blockbusters (such as weight loss drugs), often sees this oscillator rise above 70 on positive clinical trial news. A drop below 30 may reflect concerns about research setbacks, competition, or regulatory hurdles.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Eli-Lilly-and-Company-LLY&v=1772513841533 "RSI 14 indicator chart for the company's stock Eli Lilly and Company (LLY)")
RSI 14 Market Segment - Pharma holding
Eli Lilly (LLY) has become one of the world's most valuable pharmaceutical companies thanks to breakthroughs in obesity and diabetes treatments (Mounjaro/Zepbound). This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand: is LLY's phenomenal growth a reflection of its unique GLP-1 story, or is the entire sector overheated by a wave of biotech innovation?
RSI 14 for the overall market
Eli Lilly made breakthroughs in obesity and diabetes treatments (Mounjaro, Zepbound), becoming one of the world's most valuable pharmaceutical companies. This is a powerful fundamental story. This chart shows how general market hype, or, conversely, fear, influences stocks, allowing us to separate real demand for drugs from speculative market "temperature."
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LLY (Eli Lilly and Company)
For Eli Lilly, this chart reflects Wall Street's expectations for its "blockbusters." Analysts' price targets depend almost entirely on sales forecasts for Mounjaro and Zepbound (a diabetes/obesity treatment). Experts are trying to estimate how large this market will be, whether Lilly will be able to produce enough drugs, and how long it will dominate before competitors emerge. This is a bet on a true pharma breakthrough.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LLY-Eli-Lilly-and-Company&v=1772513841584 "A chart showing analyst consensus forecasts for the expected stock price. LLY (Eli Lilly and Company)")
The difference between the consensus estimate and the actual stock price LLY (Eli Lilly and Company)
Eli Lilly has become a leader in the pharmaceutical industry thanks to breakthrough drugs for diabetes and obesity (Mounjaro, Zepbound). This chart shows the difference between the current price and the analyst consensus forecast. It clearly shows whether experts believe the company's stunning growth will continue, or whether the current price already fully accounts for future revenue from blockbusters.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LLY-Eli-Lilly-and-Company&v=1772513841598 "A chart showing the difference between the consensus forecast and the actual stock price. LLY (Eli Lilly and Company)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Eli Lilly is experiencing a boom thanks to blockbusters in diabetes and obesity treatments (Mounjaro, Zepbound). The company is a leader in "big pharma." This chart shows analysts' overall expectations for the entire pharmaceutical sector. It helps us understand whether experts see potential for further growth in the industry or consider it overvalued.
Analysts' consensus forecast for the overall market share price
Eli Lilly is a big pharma giant whose diabetes and obesity drugs (Mounjaro) are breaking records. Healthcare is a defensive sector, but LLY's high valuation depends on optimism. This chart shows the overall market consensus. During periods of panic (risk-off), investors may take profits even in the best companies. Market sentiment influences LLY's valuation.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Eli Lilly and Company
Eli Lilly is one of the world's leading pharmaceutical companies. In recent years, their growth has exploded thanks to breakthrough drugs in diabetes and obesity treatments (Mounjaro, Zepbound). This chart reflects the market's enormous expectations surrounding the commercialization of these blockbusters and their assessment of their ability to dominate this new multi-billion-dollar niche.
AKIMA Market Segment Index - Pharma holding
Eli Lilly is a leading pharmaceutical company, having made breakthroughs in diabetes and obesity treatment (Mounjaro). This comprehensive index evaluates R&D and growth. The graph shows the average value for the segment. This benchmark is used to evaluate whether Lilly's blockbuster innovations allow it to outperform the average pharmaceutical company on this aggregate metric.
The AKIM Index for the overall market
Eli Lilly is a pharmaceutical giant undergoing transformation thanks to breakthrough drugs, particularly in diabetes and obesity treatments. This chart, showing the average market backdrop, is crucial. It allows us to assess whether Lilly's impressive growth is a unique story driven by its products or is also supported by a general macroeconomic tailwind.
